Nyxoah has committed to a major capital investment in Wallonia, Belgium, signing a long-term lease at LégiaPark in the Liège region to develop a 1,950 square meter production facility. The purpose-built site will include a 350 square meter state-of-the-art cleanroom designed in collaboration with ABN Cleanroom Technology’s Configure-to-Order Plus platform, enabling scalable neuromodulation device assembly. This additional capacity is intended to supplement Nyxoah’s existing U.S. contract manufacturing lines and is expected to double the company’s annual production throughput by late 2026, aligning with forecasted demand growth in North America, Europe and Asia.

The Wallonia expansion underscores Nyxoah’s strategic collaboration with LégiaPark and ABN Cleanroom Technology. LégiaPark will provide turnkey laboratory and office space alongside specialized storage, accelerating product transfer from R&D to final assembly. ABN’s modular cleanroom solution guarantees compliance with ISO 8 standards while allowing Nyxoah to increase cleanroom area by up to 50% within six months of initial commissioning. This integrated approach is set to create over 40 new engineering and manufacturing roles locally, reinforcing Belgium’s position as a center of excellence in life sciences.

CEO Olivier Taelman highlighted that the Belgian facility expansion is a key driver for improving gross margin, reducing per-unit manufacturing costs by an estimated 15% through localized supply-chain efficiencies and higher automation. The investment will be funded from existing cash reserves, supplemented by anticipated operating cash flow from the U.S. launch of the Genio system. With U.S. Food and Drug Administration approval secured in August 2025 and initial commercial shipments underway, Nyxoah forecasts a 60% year-over-year increase in device revenue for fiscal year 2026. Management reiterated its commitment to sustainable value creation, targeting EBITDA breakeven by Q4 2026 as production scale-up progresses.